AI Approach may Help Identify Melanoma Survivors who Face a High Risk of Cancer Recurrence

Most deaths from melanoma - the most lethal form of skin cancer - occur in patients who were initially diagnosed with early-stage melanoma and then later experienced a recurrence that is typically not detected until it has spread or metastasized.

A team led by investigators at Massachusetts General Hospital (MGH) recently developed an artificial intelligence - based method to predict which patients are most likely to experience a recurrence and are therefore expected to benefit from aggressive treatment. The method was validated in a study published in npj Precision Oncology.

Most patients with early-stage melanoma are treated with surgery to remove cancerous cells, but patients with more advanced cancer often receive immune checkpoint inhibitors, which effectively strengthen the immune response against tumor cells but also carry significant side effects.

"There is an urgent need to develop predictive tools to assist in the selection of high-risk patients for whom the benefits of immune checkpoint inhibitors would justify the high rate of morbid and potentially fatal immunologic adverse events observed with this therapeutic class," says senior author Yevgeniy R. Semenov, MD, an investigator in the Department of Dermatology at MGH.

"Reliable prediction of melanoma recurrence can enable more precise treatment selection for immunotherapy, reduce progression to metastatic disease and improve melanoma survival while minimizing exposure to treatment toxicities."

To help achieve this, Semenov and his colleagues assessed the effectiveness of algorithms based on machine learning, a branch of artificial intelligence, that used data from patient electronic health records to predict melanoma recurrence.

Specifically, the team collected 1,720 early-stage melanomas - 1,172 from the Mass General Brigham healthcare system (MGB) and 548 from the Dana-Farber Cancer Institute (DFCI) - and extracted 36 clinical and pathologic features of these cancers from electronic health records to predict patients' recurrence risk with machine learning algorithms. Algorithms were developed and validated with various MGB and DFCI patient sets, and tumor thickness and rate of cancer cell division were identified as the most predictive features.

"Our comprehensive risk prediction platform using novel machine learning approaches to determine the risk of early-stage melanoma recurrence reached high levels of classification and time to event prediction accuracy," says Semenov. "Our results suggest that machine learning algorithms can extract predictive signals from clinicopathologic features for early-stage melanoma recurrence prediction, which will enable the identification of patients who may benefit from adjuvant immunotherapy."

Wan, G., Nguyen, N., Liu, F. et al.
Prediction of early-stage melanoma recurrence using clinical and histopathologic features.
npj Precis. Onc. 6, 79, 2022. doi: 10.1038/s41698-022-00321-4

Most Popular Now

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Virtual Reality Shows Promise in Fightin…

A new study published in JMIR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MDD). Titled "Examining the Efficacy of Extended...

AXREM and Highland Marketing Partner to …

AXREM represents member companies that collectively provide UK hospitals with most of their diagnostic medical imaging technology, and radiotherapy equipment. The association has seen substantial growth in recent years, with membership...

Virtual Reality Environment for Teens ma…

Social media. The climate crisis. Political polarization. The tumult of a pandemic and online learning. Teens today are dealing with unprecedented stressors, and over the past decade their mental health...

AI Predicts Tumor-Killing Cells with Hig…

Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies. Combined with additional algorithms...

Somerset NHS Foundation Trust Works with…

Somerset NHS Foundation Trust is working with Oleeo to help to support its recruitment processes and deliver a better experience for recruitment managers and candidates. The trust, which employs 14,000 people...

Researchers Use Foundation Models to Dis…

Researchers at Mass General Brigham have harnessed the technology behind foundation models, which power tools like ChatGPT, to discover new cancer imaging biomarkers that could transform how patterns are identified...

Why Standards are Key to Building Trust …

Opinion Article by Dean Mawson, Clinical Director and Founder, DPM Digital Health Consultancy. There's considerable interest in the potential uses of AI in healthcare at the moment; but there is also...

AI Tool to Improve Heart Failure Care

UVA Health researchers have developed a powerful new risk assessment tool for predicting outcomes in heart failure patients. The researchers have made the tool publicly available for free to clinicians. The...